On October 29, Baxter fell 5.97% in Regular Trading, trading at $24.0801 per share, with turnover of $45.6943 million.
The key disclosed catalyst was an earnings update: Baxter reported third-quarter adjusted EPS of $0.58, above the $0.52 consensus estimate, and sales of $2.976 billion, above the expected $2.908 billion. The company also raised its full-year adjusted EPS outlook to $2.05-$2.15 from $1.95-$2.15 and lifted expected reported sales growth to 4%-5% from 3%-4%.
At the same time, the quarterly adjusted EPS was down from $0.69 a year earlier, even as net sales rose from $2.84 billion to $2.98 billion. The latest market move occurred after these results and guidance updates were released, with investors also digesting the year-over-year profit decline despite the top- and bottom-line beat.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments